Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727399 | 0.87 | PPOX (0.33) | — | |
| SCHEMBL3688814 | 0.81 | ESR1 (0.39) | ESR1ESR2 | |
| SCHEMBL3680437 | 0.78 | HSD17B1 (0.44) | ESR1ESR2HSD17B1HSD17B2 | |
| SCHEMBL3727418 | 0.77 | — | — | |
| SCHEMBL3722224 | 0.76 | AR (0.33) | HSD17B1 | |
| SCHEMBL3726004 | 0.76 | AR (0.33) | HSD17B1 | |
| SCHEMBL3726807 | 0.76 | AR (0.33) | HSD17B1 | |
| SCHEMBL3723555 | 0.75 | ESR1 (0.30) | ESR1ESR2 | |
| SCHEMBL3683807 | 0.75 | RPS6KA3 (0.30) | ESR1ESR2 | |
| SCHEMBL3726783 | 0.72 | PPOX (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210524-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, ESR2 | ESR1 1/4885ESR2 3/4885HSD17B1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.